U.S. Pharmaceuticals & Biotech Top Stock Picks from Analysts

Zoetis

Market Cap: US$31.5b

Engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally.

Insmed

Market Cap: US$25.6b

Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.

Summit Therapeutics

Market Cap: US$12.0b

A biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies.

Ionis Pharmaceuticals

Market Cap: US$10.6b

A commercial-stage biotechnology company, provides RNA-targeted medicines in the United States.

ImmunityBio

Market Cap: US$9.3b

A biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient’s immune system and deliver durable protection against cancer and infectious diseases.

Praxis Precision Medicines

Market Cap: US$9.3b

A clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States.

Vaxcyte

Market Cap: US$8.6b

A clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.

CRISPR Therapeutics

Market Cap: US$5.4b

A gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform.

Oruka Therapeutics

Market Cap: US$5.3b

A clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications.

Legend Biotech

Market Cap: US$5.3b

Through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.

Caris Life Sciences

Market Cap: US$5.1b

An artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally.

Viking Therapeutics

Market Cap: US$4.8b

A clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.

Dyne Therapeutics

Market Cap: US$4.0b

A clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States.

Structure Therapeutics

Market Cap: US$3.9b

A clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States.

Beam Therapeutics

Market Cap: US$3.6b

A biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States.

Ultragenyx Pharmaceutical

Market Cap: US$3.4b

A biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific.

uniQure

Market Cap: US$3.1b

Develops treatments for patients suffering from rare and other devastating diseases in the United States.

Vera Therapeutics

Market Cap: US$3.0b

A clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases.

Tarsus Pharmaceuticals

Market Cap: US$2.8b

A commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States.

Immunome

Market Cap: US$2.7b

A biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States.

BioCryst Pharmaceuticals

Market Cap: US$2.7b

A biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases.

Kailera Therapeutics

Market Cap: US$2.7b

Operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions.

SELLAS Life Sciences Group

Market Cap: US$2.7b

A late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States.

Mineralys Therapeutics

Market Cap: US$2.6b

A biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States.

Kodiak Sciences

Market Cap: US$2.5b

A clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases.

Nektar Therapeutics

Market Cap: US$2.5b

A biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally.

Ocular Therapeutix

Market Cap: US$2.3b

A biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States.

Zai Lab

Market Cap: US$2.2b

A biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases.

Viridian Therapeutics

Market Cap: US$2.2b

Engages in discovering, developing, and commercializing treatments for serious and rare diseases.

AbCellera Biologics

Market Cap: US$2.2b

Engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.

Syndax Pharmaceuticals

Market Cap: US$2.2b

A commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.

Palvella Therapeutics

Market Cap: US$2.2b

A clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases.

Intellia Therapeutics

Market Cap: US$2.2b

Operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies.

ADMA Biologics

Market Cap: US$2.1b

A biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.

Nuvation Bio

Market Cap: US$2.1b

A clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment.

Taysha Gene Therapies

Market Cap: US$2.1b

A clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system.